ColoAlert Test – 24.10.2018


Important Information About Colorectal Cancer

According to World Health Organization experts estimate that 940,000 new cases of colorectal cancer occur annually worldwide, leading to 500,000 deaths thereafter. Therefore, this type of cancer is one of the leading cancers among non-sex-specific cancers.

The good news is that colorectal cancer need to 10 to 15 years to develop, and when detected as early as stage 1 or 2, it is completely curable in 90% of cases. In contrast, if the cancer has already spread (stage 4), the chance of recovery drops to less than 10%. Therefore, colorectal cancer screening and early detection is critical importance.

Keywords: Sensitivity and Specificity

Very simply, sensitivity can be explained as the diagnosis rate (Real positivity rate). A test with a sensitivity of 90% correctly identifies 90 out of 100 patients. Specificity is the proportion of correctly detected negative results (Real negativity rate). Therefore, a test with a specificity of 90% falsely detects disease in only 10 out of 100 healthy individuals.

Leading Oncologists Recommendations

A growing number of oncologists are recommending that screening for colorectal cancer be performed as from the age of 40. If there are known cases of cancer in the family, screening should begin even earlier. In the field of colorectal cancer screening, colonoscopy is considered the gold standard. However, due to the psychological and physical stress caused by colonoscopy, simpler and non-invasive methods are being developed. An annual ‘fecal occult blood test’ is generally recommended to prevent the majority of the population from avoiding colorectal cancer screening. For this, only a simple stool sample is sufficient and does not require invasive intervention. However, unfortunately, due to the low sensitivity of the occult blood test singly, many colorectal cancer cases cannot be detected for a long time.

Genetic Diagnosis: The Key to Achievement

In the ColoAlert test, laboratory professionals use a highly precise method of molecular-genetic analysis. With this method, it is aimed to detect tumor tissue that has an altered DNA structure compared to healthy cells, and its sensitivity is over 85 % (percent).

“ColoAlert effectively reduces the analytical gap between colonoscopy and non-invasive testing by detecting tumor DNA.”


Prof. Dr. M. Dollinger

ColoAlert Studies

Chief Physician of Landshut


ColoAlert Test Offers You Many Benefits

Current Studies on ColoAlert:

In a multicenter study conducted by Martin-Luther-University Halle-Wittenberg and Leipzig University Hospital, 626 patients; was examined in Germany in parallel with the occult blood test, M2 pyruvate kinase (M2-PK) and tumor DNA analyses. These three non-invasive tests were compared for their analytical quality with the gold standard colonoscopy. While the occult blood test was convincing due to its high specificity (probability of determining a healthy individual as healthy), it was found to be the test with the lowest sensitivity (detection rate). M2-PK showed the opposite result. While it can increase the sensitivity by at least 6% if used together with the occult blood test, it was still found to be non-specific. ColoAlert has achieved the most accurate predictive value among non-invasive methods: a high sensitivity of 85%, as well as a specificity of 90% in the detection of colorectal cancer. These values are requested by leading oncology guidelines. In many other clinical studies, it has been shown that the detection of tumor DNA is of great benefit in the prevention of colorectal cancer. This confirms the accuracy of ColoAlert.

It is a non-invasive (non-invasive) method.

It provides a high sensitivity of 85% and a recommended specificity of at least 90%.

It is a test method that directly detects tumor DNA.

It increases the detection rate of colorectal cancer at an early stage approximately four times, significantly increasing the chance of recovery.

It is convenient and easy.